Revvity, Inc.

Revvity, Inc.

RVTYNYSE / NASDAQHealthcareMid cap

$145.22-$6.37 (-4.2%)

Last close · Data as of Nov 20, 2026

Market cap
$11.4B
P/E
47.4x
EV / EBITDA
18.2x
Revenue
$2.9B
Net margin
8.4%
ROCE
3.3%

+54.5% over the last year

Revvity, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-6.9%
3M
+17.0%
6M
+53.2%
1Y
+54.5%
5Y
-23.1%

52-week range

Day change -$6.37 (-4.2%) from $152 to $145 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RVTY, bought on each weekday since 2021.

News & filings

What Revvity filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthThe price is 26.1% above its 200-day average, and the 50-day average is above the 200-day.

Concerns (1)

  • Return on equity of 3.3% against a peer median of 10.9%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Revvity, Inc. provides health sciences solutions, technologies, and services.

Read moreShow less

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
112.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$11.4B
P/E
47.4x
P/B
1.6x
EV / EBITDA
18.2x
EV / Sales
4.9x
P/S
4.0x
52-week high
$165.78
52-week low
$82.26

Profitability

Operating margin
12.5%
Net margin
8.4%
EBITDA margin
26.8%
ROE
3.3%
ROCE
3.3%
ROA
2.0%
Asset turnover
0.23

Growth

Revenue
$2.9B
Revenue growth, 1Y
3.7%
Revenue CAGR, 3Y
-4.8%
Net profit growth, 1Y
-10.8%
Free cash flow
$509.4M

Solvency

Current ratio
1.68
Debt / Equity
0.47
Debt / Assets
0.28
CFO / Net profit
2.42
Cash / Market cap
8.1%

Where the revenue went

Of every $100 of FY2025 revenue, $8 was left as net income.

Revvity, Inc. income statement flow, FY2025
Revvity, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.3B
RevenueGross profit$1.6B
Gross profitOperating expenses$1.2B
Gross profitOperating income$356.6M
Operating incomePretax income$268.3M
Operating incomeInterest and other expense$88.4M
Pretax incomeTax and other$27.1M
Pretax incomeNet income$241.2M

Revenue and net profit

Revenue grew 3.7% in FY2025; net profit is the dashed line.

Revvity, Inc. revenue and net profit by fiscal year
Revvity, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.3B$569.2M
FY2023$2.8B$693.1M
FY2024$2.8B$270.4M
FY2025$2.9B$241.2M

Cash flows

FY2025: $582.9M from operations, $509.4M free after investment (dashed).

Revvity, Inc. operating and free cash flow by fiscal year
Revvity, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$679.8M$594.2M
FY2023$91.3M$9.9M
FY2024$628.3M$541.7M
FY2025$582.9M$509.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.9B+3.7%1Y
EBITDA
$765.8M-8.9%1Y
Net profit
$241.2M-10.8%1Y
Cash from operations
$582.9M-7.2%1Y
Free cash flow
$509.4M-6.0%1Y
Revenue CAGR, 3Y
-4.8%
Net profit CAGR, 3Y
-24.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.9B$765.8M$241.2M$509.4M3.3%+3.7%-10.8%

Monthly returns

Month-by-month returns of RVTY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$12.2B
Liabilities$4.9B
Equity$7.3B
Paid-in capital$1.3B
Retained earnings$6.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RVTY highlighted.

P/E against peers

RVTY trades at 47.4x earnings against a peer median of 44.3x.

Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Revvity, Inc.RVTYthis company$11.4B47.4x1.6x3.3%18.2x
BrightSpring Health Services, Inc.BTSG$11.3B59.4x6.0x10.2%30.3x
Molina Healthcare, Inc.MOH$10.0B21.3x2.5x11.6%—
Baxter International Inc.BAX$10.0B-10.4x1.6x-15.6%23.2x
Krystal Biotech, Inc.KRYS$9.1B44.3x7.4x16.8%51.2x
Charles River Laboratories International, Inc.CRL$8.9B—2.8x-4.6%27.5x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Peer median—44.3x3.6x10.9%30.3x

Year-to-date ROI

RVTY since 1 January, against earlier years.

Historical volatility

RVTY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Revvity, Inc. operating margin by fiscal year
Revvity, Inc. operating margin by fiscal year
DateOperating margin
FY202222.4%
FY202310.9%
FY202412.6%
FY202512.5%
LineFY2025
Cost of revenueCost Of Revenue$1.3B
Gross profitGross Profit$1.6B
Operating expensesOperating Expense$1.2B
Research and developmentResearch And Development$215.8M
Selling, general and administrativeSelling General And Administration$991.9M
Total expensesTotal Expenses$2.5B
Pretax incomePretax Income$268.3M

Learn while you research

Academy chapters picked for Revvity, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 47.4, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →